Brown Advisory’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$158M Buy
540,600
+40,661
+8% +$13.4M 0.26% 81
2025
Q4
$175M Buy
499,939
+19,760
+4% +$6.68M 0.24% 77
2025
Q3
$155M Buy
480,179
+83,559
+21% +$26M 0.2% 91
2025
Q2
$154M Sell
396,620
-28,706
-7% -$11.5M 0.2% 84
2025
Q1
$185M Buy
425,326
+1,283
+0.3% +$515K 0.26% 72
2024
Q4
$156M Buy
424,043
+24,785
+6% +$10.4M 0.2% 90
2024
Q3
$208M Sell
399,258
-2,876
-0.7% -$1.54M 0.26% 73
2024
Q2
$218M Buy
402,134
+8,534
+2% +$4.51M 0.28% 72
2024
Q1
$204M Buy
393,600
+4,486
+1% +$2.23M 0.27% 78
2023
Q4
$183M Buy
389,114
+2,138
+0.6% +$989K 0.26% 80
2023
Q3
$168M Buy
386,976
+2,551
+0.7% +$1.16M 0.28% 79
2023
Q2
$171M Sell
384,425
-6,090
-2% -$2.81M 0.27% 82
2023
Q1
$180M Sell
390,515
-2,616
-0.7% -$1.24M 0.3% 78
2022
Q4
$202M Sell
393,131
-16,053
-4% -$8.15M 0.37% 66
2022
Q3
$186M Buy
409,184
+784
+0.2% +$375K 0.36% 67
2022
Q2
$197M Sell
408,400
-10,530
-3% -$5.21M 0.37% 66
2022
Q1
$206M Sell
418,930
-8,682
-2% -$3.97M 0.31% 77
2021
Q4
$198M Buy
427,612
+2,282
+0.5% +$960K 0.25% 85
2021
Q3
$159M Sell
425,330
-860
-0.2% -$327K 0.23% 89
2021
Q2
$163M Buy
426,190
+1,264
+0.3% +$483K 0.25% 88
2021
Q1
$153M Buy
424,926
+15,214
+4% +$4.89M 0.26% 85
2020
Q4
$132M Sell
409,712
-3,188
-0.8% -$978K 0.23% 88
2020
Q3
$111M Sell
412,900
-2,674
-0.6% -$719K 0.23% 88
2020
Q2
$109M Sell
415,574
-1,781
-0.4% -$475K 0.25% 84
2020
Q1
$94.8M Sell
417,355
-6,640
-2% -$1.81M 0.29% 77
2019
Q4
$128M Buy
423,995
+17,537
+4% +$4.83M 0.32% 67
2019
Q3
$97.6M Sell
406,458
-16,853
-4% -$4.62M 0.27% 73
2019
Q2
$119M Sell
423,311
-26,997
-6% -$7.37M 0.34% 65
2019
Q1
$129M Sell
450,308
-12,567
-3% -$3.63M 0.37% 60
2018
Q4
$122M Sell
462,875
-295
-0.1% -$81.1K 0.41% 54
2018
Q3
$127M Buy
463,170
+2,061
+0.4% +$535K 0.36% 59
2018
Q2
$110M Buy
461,109
+110,458
+32% +$25.6M 0.34% 63
2018
Q1
$77M Sell
350,651
-24,736
-7% -$5.81M 0.25% 82
2017
Q4
$84.5M Sell
375,387
-10,638
-3% -$2.27M 0.27% 82
2017
Q3
$73.3M Sell
386,025
-580,332
-60% -$110M 0.24% 93
2017
Q2
$182M Buy
966,357
+482,868
+100% +$86.8M 0.56% 49
2017
Q1
$80M Sell
483,489
-22,849
-5% -$3.63M 0.27% 83
2016
Q4
$72.8M Sell
506,338
-17,407
-3% -$2.33M 0.26% 83
2016
Q3
$65.6M Sell
523,745
-2,873
-0.5% -$371K 0.23% 81
2016
Q2
$69.2M Sell
526,618
-388,965
-42% -$53.2M 0.24% 78
2016
Q1
$127M Buy
915,583
+11,827
+1% +$1.58M 0.44% 53
2015
Q4
$126M Sell
903,756
-96,823
-10% -$13.3M 0.43% 51
2015
Q3
$140M Buy
1,000,579
+20,860
+2% +$3.13M 0.5% 49
2015
Q2
$161M Sell
979,719
-47,245
-5% -$7.55M 0.52% 44
2015
Q1
$159M Buy
1,026,964
+46,312
+5% +$6.59M 0.5% 45
2014
Q4
$123M Buy
980,652
+21,650
+2% +$2.68M 0.39% 52
2014
Q3
$115M Buy
959,002
+138,423
+17% +$15.9M 0.37% 50
2014
Q2
$88.3M Buy
820,579
+2,539
+0.3% +$262K 0.28% 52
2014
Q1
$81.4M Sell
818,040
-662
-0.1% -$59.9K 0.26% 54
2013
Q4
$75.6M Sell
818,702
-72,197
-8% -$6.42M 0.25% 62
2013
Q3
$74.5M Sell
890,899
-107,951
-11% -$9.25M 0.27% 55
2013
Q2
$81.7M Buy
+998,850
New +$74.8M 0.33% 52

Other funds holding ELV

Brown Advisory's ELV Position: Q1 2026 in Review

Brown Advisory increased its Elevance Health (ELV) stake by 8.1% in Q1 2026, buying an estimated $13.4M and bringing the position to 540,600 shares worth $158M. The position accounts for 0.26% of the portfolio, ranked #81.

Brown Advisory first reported a position in ELV in Q2 2013 and has held it in 52 quarters since. The position peaked at $218M in Q2 2024. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

  • Brown Advisory held 540,600 shares of Elevance Health worth $158M as of Q1 2026.
  • Brown Advisory bought 40,661 Elevance Health shares in Q1 2026, an estimated $13.4M.
  • Elevance Health made up 0.26% of Brown Advisory's portfolio in Q1 2026, its #81 holding.
  • Brown Advisory first reported a position in Elevance Health in Q2 2013 and has held it in 52 quarters since.
  • Brown Advisory's Elevance Health position peaked at $218M in Q2 2024.
  • 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on Brown Advisory's 13F filing for Q1 2026, filed 15 May 2026.